Interpretation to SOGC clinical practice guideline: No. 362-Ovulation Induction in Polycystic Ovary Syndrome
10.3760/cma.j.cn101441-20190817-00361
- VernacularTitle:2018 SOGC多囊卵巢综合征诱导排卵实践指南(No. 362)解读
- Author:
Qiaoli ZHANG
1
;
Chanwei JIA
1
;
Liying ZHOU
1
;
Yanjun LIU
1
;
Lan YU
1
;
Xiaoyu XU
1
;
Shuyu WANG
1
Author Information
1. 首都医科大学附属北京妇产医院生殖医学中心 100026
- Publication Type:Journal Article
- Keywords:
Polycystic ovary syndrome;
Ovulation induction;
Insulin resistance;
Lifestyle modifications;
Fertilization in vitro
- From:
Chinese Journal of Reproduction and Contraception
2020;40(8):695-700
- CountryChina
- Language:Chinese
-
Abstract:
Polycystic ovary syndrome (PCOS), a common clinical endocrine disorder, is the main cause of anovulatory infertility in women of childbearing age. The clinical practice guideline for ovulation induction in PCOS patients has been supported by the Society of Obstetricians and Gynaecologists of Canada (SOGC) in 2018. First line management of infertility once a diagnosis of PCOS is made should include weight loss and lifestyle modifications. Subsequently, first line medical therapy for ovulation induction should include selective estrogen receptor modulator—clomiphene citrate (CC) and aromatase inhibitor—letrozole (LE). The gonadotropins (Gn) should be considered as the second-line medical therapy, and in vitro fertilization treatment should be the third-line medical therapy. Insulin resistant patients can take the insulin sensitizer—metformin. When there are other indications for laparoscopy, laparoscopic ovarian drilling (LOD) may be considered in cases of CC or LE resistant PCOS. The clinical preventive action, that individual and progressive principles should be followed to normalize ovulation induction in PCOS patients.
